Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 3 (2006), Issue 10 (October)

1. Effect of vitamin E on tamoxifen-treated breast cancer cells.
   Surgery, 140(4): 607-14; discussion 614-5. [Abstract] [Full-text]
2. Selective or routine axillary disease staging for patients with clinically lymph node-negative breast cancer?
   Surgery, 140(4): 500-7; discussion 507-8. [Abstract] [Full-text]
3. Accelerated partial-breast irradiation using proton beams: initial clinical experience.
   Int J Radiat Oncol Biol Phys, 66(3): 691-8. [Abstract] [Full-text]
4. Time trends of breast cancer survival in Europe in relation to incidence and mortality.
   Int J Cancer, 119(10): 2417-22. [Abstract] [Full-text]
5. The effect of timing of radiotherapy after breast-conserving surgery in patients with positive or close resection margins, young age, and node-negative disease, with long term follow-up.
   Int J Radiat Oncol Biol Phys, 66(3): 687-90. [Abstract] [Full-text]
6. High-dose simultaneously integrated breast boost using intensity-modulated radiotherapy and inverse optimization.
   Int J Radiat Oncol Biol Phys, 66(3): 923-30. [Abstract] [Full-text]
7. Serum concentrations of estrogens, sex hormone-binding globulin, and androgens and risk of breast cancer in postmenopausal women.
   Int J Cancer, 119(10): 2402-7. [Abstract] [Full-text]
8. Planning the breast tumor bed boost: changes in the excision cavity volume and surgical scar location after breast-conserving surgery and whole-breast irradiation.
   Int J Radiat Oncol Biol Phys, 66(3): 680-6. [Abstract] [Full-text]
9. Evaluation of models to predict BRCA germline mutations.
   Br J Cancer, 95(7): 914-20. [Abstract] [Full-text]
10. Ten-year follow-up results of a randomised controlled study comparing level-I vs level-III axillary lymph node dissection for primary breast cancer.
    Br J Cancer, 95(7): 811-6. [Abstract] [Full-text]
11. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer.
    Br J Cancer, 95(7): 801-10. [Abstract] [Full-text]
12. Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer.
    Br J Cancer, 95(7): 794-800. [Abstract] [Full-text]
13. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial.
    Br J Cancer, 95(7): 788-93. [Abstract] [Full-text]
14. Methyl-beta-cyclodextrin enhances the susceptibility of human breast cancer cells to carboplatin and 5-fluorouracil: involvement of Akt, NF-kappaB and Bcl-2.
    Toxicol Appl Pharmacol, 216(2): 177-85. [Abstract] [Full-text]
15. Suicide after breast cancer: an international population-based study of 723,810 women.
    J Natl Cancer Inst, 98(19): 1416-9. [Abstract] [Full-text]
16. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women.
    J Natl Cancer Inst, 98(19): 1406-15. [Abstract] [Full-text]
17. Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium.
    J Natl Cancer Inst, 98(19): 1382-96. [Abstract] [Full-text]
18. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial.
    Nat Clin Pract Oncol, 3(10): 540-51. [Abstract] [Full-text]
19. Breast cancer expression profiling: the impact of microarray testing on clinical decision making.
    Expert Opin Pharmacother, 7(15): 2069-78. [Abstract] [Full-text]
20. Update on the use of aromatase inhibitors in breast cancer.
    Expert Opin Pharmacother, 7(14): 1919-30. [Abstract] [Full-text]
21. Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data.
    Am J Clin Oncol, 29(5): 490-4. [Abstract] [Full-text]
22. A phase II study of docetaxel, doxorubicin, and infusional 5-fluorouracil in the treatment of patients with locally advanced breast cancer.
    Am J Clin Oncol, 29(5): 484-9. [Abstract] [Full-text]
23. Computed tomography (CT) scan evaluation of late toxicity following hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) in breast cancer patients treated with conservative surgery.
    Am J Clin Oncol, 29(5): 479-83. [Abstract] [Full-text]
24. Three-dimensional conformal external beam radiotherapy (3D-CRT) for accelerated partial breast irradiation (APBI): what is the correct prescription dose?
    Am J Clin Oncol, 29(5): 474-8. [Abstract] [Full-text]
25. Prolactin and breast cancer risk.
    Cancer Lett, 243(2): 160-9. [Abstract] [Full-text]
26. Breast cancer markers.
    Cancer Lett, 243(2): 145-59. [Abstract] [Full-text]
27. Metastases to the pineal gland.
    Neurology, 67(7): 1303-4. [Abstract] [Full-text]
28. Disruption of focal adhesion kinase slows transendothelial migration of AU-565 breast cancer cells.
    Biochem Biophys Res Commun, 350(2): 405-12. [Abstract] [Full-text]
29. Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells.
    Cancer Sci, 97(11): 1198-204. [Abstract] [Full-text]
30. Cost-effectiveness analysis of screening modalities for breast cancer in Japan with special reference to women aged 40-49 years.
    Cancer Sci, 97(11): 1242-7. [Abstract] [Full-text]
31. The consensus coding sequences of human breast and colorectal cancers.
    Science, 314(5797): 268-74. [Abstract] [Full-text]
32. Characterization of the breast cancer associated ATM 7271T>G (V2424G) mutation by gene expression profiling.
    Genes Chromosomes Cancer, 45(12): 1169-81. [Abstract] [Full-text]
33. Specific changes in the proteomic pattern produced by the BRCA1-Ser1841Asn missense mutation.
    Int J Biochem Cell Biol, 39(1): 220-6. [Abstract] [Full-text]
34. Routine histologic examination of 728 mastectomy scars: did it benefit our patients?
    Plast Reconstr Surg, 118(6): 1288-92. [Abstract] [Full-text]
35. Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India.
    BMC Med Genet, 7: 75. [Abstract] [Full-text]
36. Postmastectomy radiation and survival in older women with breast cancer.
    J Clin Oncol, 24(30): 4901-7. [Abstract] [Full-text]
37. Quality of life for women diagnosed with breast carcinoma in situ.
    J Clin Oncol, 24(30): 4875-81. [Abstract] [Full-text]
38. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer.
    J Clin Oncol, 24(30): 4888-94. [Abstract] [Full-text]
39. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    J Clin Oncol, 24(30): 4895-900. [Abstract] [Full-text]
40. What is the impact of shared decision making on treatment and outcomes for older women with breast cancer?
    J Clin Oncol, 24(30): 4908-13. [Abstract] [Full-text]
41. A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH.
    Oncogene, 25(49): 6544-53. [Abstract] [Full-text]
42. Estradiol regulates the insulin-like growth factor-I (IGF-I) signalling pathway: a crucial role of phosphatidylinositol 3-kinase (PI 3-kinase) in estrogens requirement for growth of MCF-7 human breast carcinoma cells.
    Biochem Biophys Res Commun, 350(4): 916-21. [Abstract] [Full-text]
43. Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer.
    BMC Cancer, 6: 248. [Abstract] [Full-text]
44. Pharmacokinetics and toxicity of weekly docetaxel in older patients.
    Clin Cancer Res, 12(20): 6100-5. [Abstract] [Full-text]
45. Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival.
    Clin Cancer Res, 12(20): 6037-42. [Abstract] [Full-text]
46. The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer.
    Clin Cancer Res, 12(20): 6000-4. [Abstract] [Full-text]
47. The potential of BORIS detected in the leukocytes of breast cancer patients as an early marker of tumorigenesis.
    Clin Cancer Res, 12(20): 5978-86. [Abstract] [Full-text]
48. Ashkenazi Jews and breast cancer: the consequences of linking ethnic identity to genetic disease.
    Am J Public Health, 96(11): 1979-88. [Abstract] [Full-text]
49. Lobular intraepithelial neoplasia [lobular carcinoma in situ] with comedo-type necrosis: A clinicopathologic study of 18 cases.
    Am J Surg Pathol, 30(11): 1445-53. [Abstract] [Full-text]
50. Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing.
    Am J Surg Pathol, 30(11): 1357-66. [Abstract] [Full-text]
51. Multidrug resistance in locally advanced breast cancer.
    Tumour Biol, 27(6): 309-18. [Abstract] [Full-text]
52. MC1R common variants, CDKN2A and their association with melanoma and breast cancer risk.
    Int J Cancer, 119(11): 2597-602. [Abstract] [Full-text]
53. Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients.
    Int J Cancer, 119(11): 2539-45. [Abstract] [Full-text]
54. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer.
    Invest New Drugs, 25(1): 41-8. [Abstract] [Full-text]
55. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer.
    Invest New Drugs, 25(1): 63-7. [Abstract] [Full-text]
56. Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy.
    J Clin Oncol, 24(31): 4971-5. [Abstract] [Full-text]
57. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer.
    J Clin Oncol, 24(31): 4956-62. [Abstract] [Full-text]
58. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer.
    J Clin Oncol, 24(31): 4963-70. [Abstract] [Full-text]
59. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting.
    J Clin Oncol, 24(31): 5091-7. [Abstract] [Full-text]
60. Increased sister chromatid exchange frequency in young women with breast cancer and in their first-degree relatives.
    Cancer Genet Cytogenet, 171(1): 65-7. [Abstract] [Full-text]
61. Reduction in nonfluorescence state of quantum dots on an immunofluorescence staining.
    Biochem Biophys Res Commun, 351(1): 7-13. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.